United States was NovoCure’s largest region in fiscal 2025, bringing in $385.63M of $655.35M (59%).
| Geography | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $406.89M | $349.74M | $391.80M | $385.63M | |||||||||
| Germany | $46.12M | $60.21M | $65.26M | $79.41M | |||||||||
| France | — | $11.74M | $55.73M | $76.19M | |||||||||
| Other International Markets | $30.71M | $32.76M | $42.47M | $56.90M | |||||||||
| Japan | $32.78M | $31.67M | $32.57M | $37.79M | |||||||||
| Greater China | $21.33M | $23.22M | $17.39M | $19.44M | |||||||||
| Emea | — | — | — | — | |||||||||
| Other Emea | — | — | — | — | |||||||||
| Europe, Israel & Japan | — | — | — | — | |||||||||
| Total | $537.84M | $509.34M | $605.22M | $655.35M |
NovoCure brought in $655.35M from its six regions in fiscal 2025, the year ended December 31, 2025. That was up 8.3% from $605.22M in fiscal 2024. United States was the largest at $385.63M (58.8%), ahead of Germany at $79.41M (12.1%) and France at $76.19M (11.6%). The other three regions brought in $114.13M combined.
Compared with fiscal 2024, France grew fastest, up 36.7% to $76.19M, while United States fell the most, down 1.6% to $385.63M.
NovoCure began breaking out France in fiscal 2023, when it brought in $11.74M.
Reporting Period was NovoCure’s largest revenue line in fiscal 2025, bringing in $632.36M of $655.35M (96%).
| Revenue, Performance Obligation, Period Obligation Was Satisfied In | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Reporting Period | $480.27M | $492.09M | $568.82M | $632.36M | |
| Previous Periods | $57.57M | $17.25M | $36.40M | $23.00M | |
| Total | $537.84M | $509.34M | $605.22M | $655.35M |
NovoCure brought in $655.35M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 8.3% from $605.22M in fiscal 2024. Reporting Period was the largest at $632.36M (96.5%), ahead of Previous Periods at $23.00M (3.5%).
Compared with fiscal 2024, Reporting Period grew 11.2% to $632.36M, while Previous Periods fell 36.8% to $23.00M. From fiscal 2022 to 2025, combined revenue from these revenue lines grew from $537.84M to $655.35M, a compound annual growth rate of 6.8%. Reporting Period's share of the total rose from 89.3% to 96.5%.
NovoCure (NVCR) reports its revenue by geography and by revenue, performance obligation, period obligation was satisfied in. In fiscal 2025, United States was its largest region, bringing in $385.63M (58.8% of the total), followed by Germany at $79.41M (12.1%).
United States was NovoCure's largest region in fiscal 2025, bringing in $385.63M, or 58.8% of the $655.35M total across its six regions.
Reporting Period was NovoCure's largest revenue line in fiscal 2025, bringing in $632.36M, or 96.5% of the $655.35M total across its two revenue lines.
Among NovoCure's regions that make up at least 2% of revenue, France grew fastest in fiscal 2025, up 36.7% from $55.73M to $76.19M.
Every figure comes from NovoCure's annual financial filings, as reported. Each line keeps the name NovoCure gives it, and years follow its fiscal calendar.
NovoCure's revenue by geography goes back to fiscal 2013, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.